» Articles » PMID: 27025497

Family History Predictors of BRCA1/BRCA2 Mutation Status Among Tunisian Breast/ovarian Cancer Families

Overview
Journal Breast Cancer
Specialty Oncology
Date 2016 Mar 31
PMID 27025497
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: With the increasing request for BRCA1/BRCA2 mutation tests, several risk models have been developed to predict the presence of mutation in these genes; in this study, we have developed an efficient BRCA genetic testing strategy.

Method: As first step, to identify predictor variables associated with BRCA status, we have undertaken a cumulative mutation analysis including data from three Tunisian studies. Then, we have developed a logistic regression model for predicting the likelihood of harboring a BRCA mutation. Using receiver operating characteristic curves (ROC), an effective evaluation was performed. A total of 92 Tunisian families were included. Overall, 27 women were positive for BRCA1/BRCA2 deleterious mutations.

Results: Tow recurrent mutations (c.211dupA and c.5266dupC) explained 76 % of BRCA1-related families and three recurrent mutations (c.1310_1313del, c.1542_1547delAAGA and c.7887_7888insA) explained 90 % of BRCA2-related families. Early age at diagnosis of breast cancer, ovarian cancer, bilateral breast cancer were associated with BRCA1, whereas male breast cancer and four or more breast cancer cases in the family were associated with BRCA2. The area under the receiver operating characteristic curve of the risk score was 0.802 (95 % confidence interval = 0.0699-0. 905).

Conclusion: Logistic regression reported particular profiles related to BRCA germline mutation carriers in our population, as well as an efficient prediction model that may be a useful tool for increasing the cost-effectiveness of genetic testing strategy.

Citing Articles

Finding significance: New perspectives in variant classification of the RAD51 regulators, BRCA2 and beyond.

Rein H, Bernstein K DNA Repair (Amst). 2023; 130:103563.

PMID: 37651978 PMC: 10529980. DOI: 10.1016/j.dnarep.2023.103563.


Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region.

Elalaoui S, Laarabi F, Afif L, Lyahyai J, Ratbi I, Cherkaoui Jaouad I Breast Cancer Res Treat. 2022; 194(1):187-198.

PMID: 35578052 DOI: 10.1007/s10549-022-06622-3.


Prevalence of Clinically Relevant Germline Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience.

van der Merwe N, Combrink H, Ntaita K, Oosthuizen J Front Genet. 2022; 13:834265.

PMID: 35464868 PMC: 9024354. DOI: 10.3389/fgene.2022.834265.


Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.

Ben Ayed-Guerfali D, Ben Kridis-Rejab W, Ammous-Boukhris N, Ayadi W, Charfi S, Khanfir A J Transl Med. 2021; 19(1):108.

PMID: 33726785 PMC: 7962399. DOI: 10.1186/s12967-021-02772-y.


A Review of Cancer Genetics and Genomics Studies in Africa.

Rotimi S, Rotimi O, Salhia B Front Oncol. 2021; 10:606400.

PMID: 33659210 PMC: 7917259. DOI: 10.3389/fonc.2020.606400.